Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
CNY 4.77
(0.0%)
CNY 4.77
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 305.75 Million CNY | -8.53% |
| 2022 | 334.27 Million CNY | 2839.21% |
| 2021 | 11.37 Million CNY | -97.74% |
| 2020 | 502.71 Million CNY | -1.61% |
| 2019 | 510.92 Million CNY | -59.07% |
| 2018 | 1.24 Billion CNY | 12.41% |
| 2017 | 1.11 Billion CNY | -2.07% |
| 2016 | 1.13 Billion CNY | 113.19% |
| 2015 | 531.88 Million CNY | -41.15% |
| 2014 | 903.79 Million CNY | 38.13% |
| 2013 | 654.29 Million CNY | 0.13% |
| 2012 | 653.45 Million CNY | 10.44% |
| 2011 | 591.7 Million CNY | 1590.57% |
| 2010 | 35 Million CNY | -30.0% |
| 2009 | 50 Million CNY | 7913.08% |
| 2008 | 623.98 Thousand CNY | -93.76% |
| 2007 | 10 Million CNY | 0.0% |
| 2006 | 10 Million CNY | 0.0% |
| 2005 | - CNY | -100.0% |
| 2004 | 30 Million CNY | -52.38% |
| 2003 | 63 Million CNY | -28.41% |
| 2002 | 88 Million CNY | 79.33% |
| 2001 | 49.07 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 137.5 Million CNY | -0.44% |
| 2024 Q2 | 138.1 Million CNY | -65.94% |
| 2024 Q1 | 406.19 Million CNY | 32.93% |
| 2023 Q1 | 375.22 Million CNY | 12.25% |
| 2023 Q2 | 346.84 Million CNY | -7.57% |
| 2023 Q3 | 308.72 Million CNY | -10.99% |
| 2023 Q4 | 305.75 Million CNY | -0.96% |
| 2023 FY | 305.75 Million CNY | -8.53% |
| 2022 Q2 | 2.63 Million CNY | -97.39% |
| 2022 Q4 | 334.27 Million CNY | 3977.23% |
| 2022 FY | 334.27 Million CNY | 2839.21% |
| 2022 Q1 | 100.62 Million CNY | 784.78% |
| 2022 Q3 | 8.19 Million CNY | 211.69% |
| 2021 Q3 | 200.02 Million CNY | -33.25% |
| 2021 Q2 | 299.67 Million CNY | -22.02% |
| 2021 Q1 | 384.29 Million CNY | -23.56% |
| 2021 FY | 11.37 Million CNY | -97.74% |
| 2021 Q4 | 11.37 Million CNY | -94.31% |
| 2020 Q4 | 502.71 Million CNY | -13.16% |
| 2020 Q1 | 496.96 Million CNY | -2.73% |
| 2020 Q3 | 578.9 Million CNY | -3.19% |
| 2020 Q2 | 597.94 Million CNY | 20.32% |
| 2020 FY | 502.71 Million CNY | -1.61% |
| 2019 Q4 | 510.92 Million CNY | 24.75% |
| 2019 Q2 | 1.23 Billion CNY | 0.08% |
| 2019 Q1 | 1.23 Billion CNY | -0.81% |
| 2019 FY | 510.92 Million CNY | -59.07% |
| 2019 Q3 | 409.55 Million CNY | -66.95% |
| 2018 Q3 | 1.24 Billion CNY | 14.02% |
| 2018 Q4 | 1.24 Billion CNY | 0.07% |
| 2018 Q2 | 1.09 Billion CNY | -0.53% |
| 2018 Q1 | 1.09 Billion CNY | -0.96% |
| 2018 FY | 1.24 Billion CNY | 12.41% |
| 2017 Q1 | 1.12 Billion CNY | -0.41% |
| 2017 FY | 1.11 Billion CNY | -2.07% |
| 2017 Q2 | 1.1 Billion CNY | -2.23% |
| 2017 Q3 | 1.1 Billion CNY | 0.03% |
| 2017 Q4 | 1.11 Billion CNY | 0.53% |
| 2016 FY | 1.13 Billion CNY | 113.19% |
| 2016 Q2 | 336.28 Million CNY | -18.93% |
| 2016 Q1 | 414.78 Million CNY | -22.02% |
| 2016 Q3 | 1.35 Billion CNY | 304.41% |
| 2016 Q4 | 1.13 Billion CNY | -16.62% |
| 2015 Q2 | 886.44 Million CNY | -4.94% |
| 2015 Q4 | 531.88 Million CNY | -46.04% |
| 2015 Q3 | 985.61 Million CNY | 11.19% |
| 2015 FY | 531.88 Million CNY | -41.15% |
| 2015 Q1 | 932.49 Million CNY | 3.18% |
| 2014 FY | 903.79 Million CNY | 38.13% |
| 2014 Q1 | 671.77 Million CNY | 2.67% |
| 2014 Q2 | 656.65 Million CNY | -2.25% |
| 2014 Q3 | 1.15 Billion CNY | 76.36% |
| 2014 Q4 | 903.79 Million CNY | -21.96% |
| 2013 Q4 | 654.29 Million CNY | 2.1% |
| 2013 FY | 654.29 Million CNY | 0.13% |
| 2013 Q3 | 640.82 Million CNY | -0.24% |
| 2013 Q2 | 642.34 Million CNY | -3.25% |
| 2013 Q1 | 663.89 Million CNY | 1.6% |
| 2012 Q4 | 653.45 Million CNY | 4.06% |
| 2012 Q3 | 627.97 Million CNY | 5.98% |
| 2012 Q2 | 592.54 Million CNY | 0.07% |
| 2012 FY | 653.45 Million CNY | 10.44% |
| 2012 Q1 | 592.12 Million CNY | 0.07% |
| 2011 Q4 | 591.7 Million CNY | -5.52% |
| 2011 Q1 | 35 Million CNY | 0.0% |
| 2011 Q2 | 625.85 Million CNY | 1688.16% |
| 2011 Q3 | 626.27 Million CNY | 0.07% |
| 2011 FY | 591.7 Million CNY | 1590.57% |
| 2010 Q2 | 50 Million CNY | 0.0% |
| 2010 FY | 35 Million CNY | -30.0% |
| 2010 Q3 | 35 Million CNY | -30.0% |
| 2010 Q1 | 50 Million CNY | 0.0% |
| 2010 Q4 | 35 Million CNY | 0.0% |
| 2009 Q1 | 646.59 Thousand CNY | 3.62% |
| 2009 FY | 50 Million CNY | 7913.08% |
| 2009 Q4 | 50 Million CNY | 0.0% |
| 2009 Q3 | 50 Million CNY | 7632.86% |
| 2009 Q2 | 646.59 Thousand CNY | 0.0% |
| 2008 Q4 | 623.98 Thousand CNY | -93.76% |
| 2008 FY | 623.98 Thousand CNY | -93.76% |
| 2008 Q3 | 10 Million CNY | 0.0% |
| 2008 Q2 | 10 Million CNY | 0.0% |
| 2008 Q1 | 10 Million CNY | 0.0% |
| 2007 Q2 | - CNY | -100.0% |
| 2007 Q3 | 24 Million CNY | 0.0% |
| 2007 FY | 10 Million CNY | 0.0% |
| 2007 Q4 | 10 Million CNY | -58.33% |
| 2007 Q1 | 10 Million CNY | 0.0% |
| 2006 Q1 | - CNY | 0.0% |
| 2006 Q3 | 25 Million CNY | 150.0% |
| 2006 Q4 | 10 Million CNY | -60.0% |
| 2006 FY | 10 Million CNY | 0.0% |
| 2006 Q2 | 10 Million CNY | 0.0% |
| 2005 FY | - CNY | -100.0% |
| 2005 Q4 | - CNY | -100.0% |
| 2005 Q3 | 30 Million CNY | 0.0% |
| 2005 Q1 | 30.52 Million CNY | 1.73% |
| 2005 Q2 | 30 Million CNY | -1.7% |
| 2004 Q2 | 63 Million CNY | 46.51% |
| 2004 Q1 | 43 Million CNY | -31.75% |
| 2004 FY | 30 Million CNY | -52.38% |
| 2004 Q4 | 30 Million CNY | -52.38% |
| 2004 Q3 | 63 Million CNY | 0.0% |
| 2003 Q4 | 63 Million CNY | 0.0% |
| 2003 FY | 63 Million CNY | -28.41% |
| 2002 FY | 88 Million CNY | 79.33% |
| 2001 FY | 49.07 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | 75.17 Million CNY | -306.718% |
| Zhangzhou Pientzehuang Pharmaceutical., Ltd | 35.44 Million CNY | -762.691% |
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. | 170.1 Million CNY | -79.751% |
| Aurora Optoelectronics Co.,Ltd. | 13.33 Million CNY | -2193.061% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | 7.23 Million CNY | -4128.074% |
| NanJing Pharmaceutical Company Limited | 2.11 Billion CNY | 85.562% |
| GuangYuYuan Chinese Herbal Medicine Co., Ltd. | 39.11 Million CNY | -681.764% |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | - CNY | -Infinity% |